Search Results for "R"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for R. Results 211 to 220 of 996 total matches.
In Brief: Hypo- and Hyperglycemia with Gatifloxacin (Tequin)
The Medical Letter on Drugs and Therapeutics • Mar 13, 2006 (Issue 1230)
., Vanderbilt School of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Neal H. Steigbigel, M.D ...
A study now available on the web site of The New England Journal of Medicine (LY Park-Wyllie et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. www.nejm.org, published online March 1, 2006) reports an increased risk of hypoglycemia (RR 4.3) and hyperglycemia (RR 16.7) with use of gatifloxacin (Tequin), a fluoroquinolone antibiotic. The Medical Letter published an article on this risk in 2003 (vol. 45, page 64); at that time the extent to which other fluoroquinolones carried the same risk was unclear. The recent report indicates that, except for a slightly increased...
In Brief: Telithromycin Hepatotoxicity
The Medical Letter on Drugs and Therapeutics • Apr 24, 2006 (Issue 1233)
, Copenhagen
Dan M. Roden, M.D., Vanderbilt School of Medicine
F. Estelle R. Simons, M.D., University ...
Telithromycin (Ketek) is an oral erythromycin derivative FDA-approved for treatment of mild to moderate community-acquired pneumonia, exacerbations of chronic bronchitis and acute bacterial sinusitis (Med Lett Drugs Ther 2004; 46:66). It is generally considered an alternative antibiotic because of its cost, potential for adverse effects including visual disturbances, exacerbation of myasthenia gravis, hepatotoxicity and drug interactions. A recent report (Ann Intern Med 2006; 144:415) described serious hepatotoxicity probably related to telithromycin in three patients, including one who died...
Correction: Panitumumab Dosage
The Medical Letter on Drugs and Therapeutics • Jun 04, 2007 (Issue 1262)
., Vanderbilt University School of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Neal H ...
In the CLINICAL STUDIES - Other Cancers paragraph (Med Lett Drugs Ther 2007; 49:35), the dosage in the first line should be 2.5 mg/kg, not 25 mg/kg.
Correction: The EarCheck Middle Ear Monitor
The Medical Letter on Drugs and Therapeutics • Aug 11, 2008 (Issue 1292)
. Roden, M.D., Vanderbilt University School of Medicine
F. Estelle R. Simons, M.D., University ...
The article in the July 14th issue contained an error in the last sentence of the last paragraph beginning on page 55. The instrument's reading is determined not by the degree of protrusion of the tympanic membrane, but rather by its mobility.
Correction: CT Colonography
The Medical Letter on Drugs and Therapeutics • Dec 15, 2008 (Issue 1301)
. Roden, M.D., Vanderbilt University School of Medicine
F. Estelle R. Simons, M.D., University ...
(Med Lett Drugs Ther 2008; 50:94) In table 1, "Invasive" should be "less" and "more" rather than "no" and "yes" for CT colonography and colonoscopy, respectively.
In Brief: A New Indication for Abemaciclib (Verzenio) (online only)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
robustness is essential for
decisionmaking in early breast cancer. Breast 2020; 51:120. 3. R Nishimura et al ...
The oral cyclin-dependent kinase (CDK) 4/6 inhibitor
abemaciclib (Verzenio – Lilly) has been approved by
the FDA for use in combination with endocrine therapy
(tamoxifen or an aromatase inhibitor) for adjuvant
treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor
2 (HER2)-negative, node-positive, early breast
cancer at high risk of recurrence.1It was previously
approved for the same indication, but patients were
also required to have a Ki-67 score ≥20%. About
70% of all breast cancers are HR-positive and HER2-negative. Ki-67 is a...
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e62-3 doi:10.58347/tml.2023.1673g | Show Introduction Hide Introduction
NovolinPen for Insulin Injection
The Medical Letter on Drugs and Therapeutics • Dec 30, 1988 (Issue 782)
are available: regular insulin (Novolin R PenFill), NPH insulin isophane (Novolin N PenFill) and a mixture of 70 ...
The NovolinPen (Squibb - Novo) is a device that uses prefilled cartridges to inject semisynthetic human insulin (Medical Letter, 25:63, 1983). Three formulations are available: regular insulin (Novolin R PenFill), NPH insulin isophane (Novolin N PenFill) and a mixture of 70% NPH and 30% regular (Novolin 70/30 PenFill). The NovolinPen is advertised as more accurate, more convenient and less expensive than conventional syringes and needles. The same device is marketed in Canada as the Novolin-Pen II (Connaught Novo). (An earlier device is also available as the Novolin-Pen in Canada and the...
Desmopressin for Nocturnal Enuresis
The Medical Letter on Drugs and Therapeutics • Apr 20, 1990 (Issue 816)
hyponatremia and
had a grand mal seizure (MFM Bamford and G Cruickshank, J R Coll Gen Pract, 39:345, 1989 ...
Desmopressin acetate (DDAVP -Rorer), a synthetic analog of the natural human antidiuretic hormone arginine vasopressin, was recently approved by the US Food and Drug Administration for treatment of primary nocturnal enuresis. DDAVP Nasal Spray, which is similar to an intranasal solution that has been available in the USA for treatment of central diabetes insipidus (Medical Letter, 20:26, 1978), will be used for the new indication.
Laparoscopic Cholecystectomy
The Medical Letter on Drugs and Therapeutics • Dec 28, 1990 (Issue 834)
, N
Engl J Med, 323:1273, Nov 1, 1990; R Winslow, Wall St J, 216:1, Dec 10, 1990).
TECHNIQUE ...
Unlike new drugs, new techniques for surgery do not need the approval of any government agency. Laparoscopic cholecystectomy, made possible by the development of miniaturized television cameras, is one such technique that has recently attracted widespread interest (LW Way, N Engl J Med, 323:1273, Nov 1, 1990; R Winslow, Wall St J, 216:1, Dec 10, 1990).
FK 506 - An Investigational Immunosuppressant
The Medical Letter on Drugs and Therapeutics • Oct 04, 1991 (Issue 854)
transplants (R
Shapiro et al, Transplant Proc, 23:920, 1991; JM Armitage et al, Transplant Proc, 23:1149 ...
FK 506 (Fujisawa), an immunosuppressant similar in activity to cyclosporine (Sandimmune - Medical Letter 25:77, 1983), is currently under investigation in the USA, Europe, and Japan for prevention of organ transplant rejection.